• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Segment 2 - Histology, Targeted Therapy and Surgery


Dr Langer suggests that historically, there's been a monolithic approach to treating NSCLC.

Dr Langer suggests that historically, there’s been a “monolithic approach” to treating NSCLC. “The histologic distinctions have really come to the forefront now in advanced disease, whereas perhaps 8 to 10 years ago it didn’t really make much of a difference,” he says, “so we are holding our pathologists’ ‘feet to the fire.’”

The panel also discusses targeted therapy and surgery in treatment of NSCLC.

Dr Sugarbaker says surgery is dynamic, noting there are a number of techniques to resect or remove the tumor with technology’s help. “These have significantly reduced the morbidity or the stress and pain for the patient.”

Related Videos
dr amy laughlin
dr kathi mooney
dr saira jan
dr saira jan
Ted Okon, MBA, Community Oncology Alliance
Miriam J. Atkins, MD, FACP, Community Oncology Alliance/AO Multispecialty Clinic
Lalan Wilfongd, MD, US Oncology Network
Dr Carmen C. Solórzano
Crystal Denlinger
Related Content
© 2023 MJH Life Sciences
All rights reserved.